Article
Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors.
Gene - 1 Mar 2022
Ismail Mohamed A, Nasrallah Gheyath K, Monne Maria, AlSayab Ali, Yassin Mohamed A, Varadharaj Govindarajulu, Younes Salma, Sorio Claudio, Cook Richard, Modjtahedi Helmout, Al-Dewik Nader I
Abstract excerpt
Tyrosine kinase inhibitors (TKIs) have remarkably transformed Ph+ chronic myeloid leukemia (CML) management; however, TKI resistance remains a major clinical challenge. Mutations in BCR-ABL1 are well studied but fail to explain 20-40% of resistant cases, suggesting the activation of alternative, BCR-ABL1-independent pathways. Protein Tyrosine Phosphatase Receptor Gamma (PTPRG), a tumor suppressor, was found to be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.